Loading...
 

Volume 35, Issue 1, March 2024



Sign in to download the Issue in PDF format.

Back to the list
Mediterr J Rheumatol 2021;32(1):15-20
Article Links
Cardiovascular Magnetic Resonance Reveals Cardiac Pathophysiology in Autoimmune Rheumatic Diseases
George Markousis-Mavrogenis1, Petros P. Sfikakis2,3, Loukia Koutsogeorgopoulou3, Theodoros Dimitroulas4, Gikas Katsifis5, Aikaterini Giannakopoulou6, Paraskevi Voulgari7, Genovefa Kolovou1, George D. Kitas8, Sophie I. Mavrogeni1,3
Authors Information
1. Onassis Cardiac Surgery Center, Athens, Greece

2. Joint Rheumatology, Laikon Hospital, Athens, Greece

3. Department of Pathophysiology, Laikon Hospital, National Kapodistrian University of Athens, Athens, Greece

4. Department of Internal Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece

5. Naval Hospital, Athens, Greece

6. Agia Sophia Children’s Hospital, Athens, Greece

7. Rheumatology Department, University of Ioannina, Ioannina, Greece 

8. Arthritis Research UK Epidemiology Unit, Manchester University, Manchester, United Kingdom

George Markousis-Mavrogenis, Theodoros Dimitroulas, Gikas Katsifis, Paraskevi Voulgari, Genovefa Kolovou, George D. Kitas, Sophie I. Mavrogeni
Keywords: Cardiovascular magnetic resonance, myocardial perfusion-fibrosis, coronary artery disease, vasculitis, myocardial inflammation
References
  1. Goldblatt F, O'Neill SG. Clinical aspects of autoimmune rheumatic diseases. Lancet 2013;382(9894):797-808.
  2. Sherer Y, Shoenfeld Y. Mechanisms of disease: atherosclerosis in autoimmune diseases. Nat Clin Pract Rheumatol 2006;2:99-106.
  3. Kitas GD, Gabriel SE. Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives. Ann Rheum Dis 2011;70:8-14.
  4. Hollan I, Meroni PL, Ahearn JM, Cohen Tervaert JW, Curran S, Goodyear CS, et al.  Cardiovascular disease in autoimmune rheumatic diseases. Autoimmun Rev 2013;12(10):1004-15.
  5. Björnådal L, Yin L, Granath F, Klareskog L, Ekbom A. Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus:  results from a Swedish population based study 1964-95. J Rheumatol 2004;31(4):713-9.
  6. Symmons DP, Gabriel SE. Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE. Nat Rev Rheumatol 2011;7(7):399-408.
  7. Gasparyan AY. Cardiovascular risk and inflammation: pathophysiological mechanisms, drug design, and targets. Curr Pharm Des 2012;18:1447-9.
  8. Dimitroulas T, Giannakoulas G, Karvounis H, Garyfallos A, Settas L, Kitas GD. Micro- and macrovascular treatment targets in scleroderma heart disease. Curr Pharm Des 2014;20(4):536-44.
  9. Al-Dhaher FF, Pope JE, Ouimet JM. Determinants of morbidity and mortality of systemic sclerosis in Canada. Semin Arthritis Rheum 2010;39:269-77.
  10. Mavrogeni SI, Kitas GD, Dimitroulas T, Sfikakis PP, Seo P, Gabriel S, et al. Cardiovascular magnetic resonance in rheumatology: Current status and recommendations for use. Int J Cardiol 2016;217:135-48.
  11. Mavrogeni S, Markousis-Mavrogenis G, Kolovou G. The Sphinx's riddle: cardiovascular involvement in autoimmune rheumatic disease. BMC Cardiovasc Disord 2016;16(1):204.
  12. Bieri O, Scheffler K. Fundamentals of balanced steady state free precession MRI. J Magn Reson Imaging 2013;38(1):2-11.
  13. Higgins C, Herfkens R, Lipton M, Sievers R, Sheldon P, Kaufman L. Nuclear magnetic resonance imaging of acute myocardial infarction in dogs: alterations in magnetic relaxation times. Am J Cardiol 1983;52(1):184-8.
  14. Knight RA, Ordidge RJ, Helpern JA, Chopp M, Rodolosi LC, Peck D. Temporal evolution of ischemic damage in rat brain measured by proton nuclear magnetic resonance imaging. Stroke 1991;22(6):802-8.
  15. Eitel I, M. Friedrich M. T2-weighted cardiovascular magnetic resonance inacutecardiac disease. J Cardiovasc Magn Res 2011;13:13.
  16. Wince W, Kim R. Molecular imaging: T2-weighted CMR of the area at risk–arisky business? Nat Rev Cardiol 2010;7(10):547-9.
  17. Giri S, Chung YC, Merchant A, Mihai G, Rajagopalan S, Raman SV, et al. T2 quantification for improved detection of myocardial edema. J Cardiovasc Magn Res 2009;11:56-69.
  18. Wassmuth R, Prothmann M, Utz W, Dieringer M, Von Knobelsdorff-Brenkenhoff F, Greiser A, et al. Variability and homogeneity of cardiovascular magnetic resonance myocardial T2-mapping in volunteers compared to patients with edema. J Cardiovasc Magn Res 2013;15:27-19.
  19. Taylor AJ, Salerno M, Dharmakumar R, Jerosch-Herold M. T1 Mapping: Basic Techniques and Clinical Applications. JACC Cardiovasc Imaging 2016;9(1):67-81.
  20. Mavrogeni SI, Bratis K, Karabela G, Spiliotis G, Wijk Kv, Hautemann D, et al. Cardiovascular Magnetic Resonance Imaging clarifies cardiac pathophysiology in early, asymptomatic diffuse systemic sclerosis. Inflamm Allergy Drug Targets 2015;14(1):29-36.
  21. Tektonidou MG, Sfikakis PP, Kolovou G, Mavrogeni S. Stress perfusion Cardiac Magnetic Resonance in Patients with Antiphospholipid Syndrome. Mediterr J Rheumatol 2018 J; 29(2):99-102.  
  22. Mavrogeni SI, Sfikakis PP, Markousis-Mavrogenis G, Bournia VK, Poulos G, Koutsogeorgopoulou L, et al. Cardiovascular magnetic resonance imaging pattern in patients with autoimmune rheumatic diseases and ventricular tachycardia with preserved ejection fraction. Int J Cardiol 2019; 284:105-9.
  23. Markousis-Mavrogenis G, Bournia VK, Panopoulos S, Koutsogeorgopoulou L, Kanoupakis G, Apostolou D, et al. Cardiovascular Magnetic Resonance Identifies High-Risk Systemic Sclerosis Patients with Normal Echocardiograms and Provides Incremental Prognostic Value. Diagnostics (Basel) 2019; 9(4):220.
  24. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008;214(2):199-210.
  25. Granitz M, Motloch LJ, Granitz C, Meissnitzer M, Hitzl W, Hergan K, et al. Comparison of native myocardial T1 and T2 mapping at 1.5T and 3T in healthy volunteers: Reference values and clinical implications. Wien Klin Wochenschr 2019;131(7-8):143-55.
  26. Haaf P, Garg P, Messroghli DR, Broadbent DA, Greenwood JP, Plein S, et al. Cardiac T1 Mapping and Extracellular Volume (ECV) in clinical practice: a comprehensive review. J Cardiovasc Magn Reson 2017;18:89.
  27. Markousis-Mavrogenis G, Bournia VK, Panopoulos S, Koutsogeorgopoulou L, Kanoupakis G, Apostolou D, etal. Cardiovascular Magnetic Resonance Identifies High-Risk Systemic Sclerosis Patients with Normal Echocardiograms and Provides Incremental Prognostic Value. Diagnostics (Basel) 2019;9(4):220.
  28. Moon JC, Messroghli DR, Kellman P, Piechnik SK, Robson MD, Ugander M, et al. Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. J Cardiovasc Magn Reson 2013;15:92.
  29. Sibley CT, Noureldin RA, Gai N, Nacif MS, Liu S, Turkbey EB, et al. T1 mapping in cardiomyopathy at cardiac MR: comparison with endomyocardial biopsy. Radiology 2012;265:724-32.
  30. Mayr A, Kitterer D, Latus J, Steubing H, Henes J, Vecchio F, et al. Evaluation of myocardial involvement in patients with connective tissue disorders: a multi-parametric cardiovascular magnetic resonance study. J Cardiovasc Magn Reson 2016;18(1):67.
  31. von Knobelsdorff-Brenkenhoff F, Schulz-Menger J. Role of cardiovascular magnetic resonance in the guidelines of the European Society of Cardiology. J Cardiovasc Magn Reson 2016;18:6.
  32. Mavrogeni SI, Sfikakis PP. Systemic lupus erythematosus with antiphospholipid syndrome: Cardiovascular magnetic resonance for evaluation of cardiac hypertrophy. Mediterr J Rheumatol 2017 Dec;28(4):221-2.
  33. Friedrich MG, Sechtem U, Schulz-Menger J, Holmvang G, Alakija P, Cooper LT, White JA, et al. Cardiovascular magnetic resonance in myocarditis: A JACC White Paper. J Am Coll Cardiol 2009;53(17):1475-87.